CVS Caremark Rating Lowered to Underperform at ISI Group (CVS)
CVS Caremark (NYSE:CVS) was downgraded by equities researchers at ISI Group to an “underperform” rating in a research report issued on Tuesday. They currently have a $54.00 target price on the stock, down from their previous target price of $86.00. ISI Group’s price objective points to a potential downside of 30.21% from the company’s current price.
CVS Caremark (NYSE:CVS) traded down 0.71% on Tuesday, hitting $76.82. 5,342,732 shares of the company’s stock traded hands. CVS Caremark has a 52-week low of $56.32 and a 52-week high of $79.43. The stock has a 50-day moving average of $76.8 and a 200-day moving average of $74.16. The company has a market cap of $90.110 billion and a price-to-earnings ratio of 19.70. CVS Caremark also was the recipient of unusually large options trading on Monday. Investors bought 7,359 put options on the stock. This is an increase of 776% compared to the typical daily volume of 840 put options.
CVS Caremark (NYSE:CVS) last announced its earnings results on Tuesday, August 5th. The company reported $1.13 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.10 by $0.03. The company had revenue of $34.60 billion for the quarter, compared to the consensus estimate of $33.47 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts predict that CVS Caremark will post $4.46 earnings per share for the current fiscal year.
CVS has been the subject of a number of other recent research reports. Analysts at Susquehanna raised their price target on shares of CVS Caremark from $85.00 to $90.00 in a research note on Friday, June 6th. They now have a “positive” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of CVS Caremark in a research note on Thursday, May 29th. They now have a $81.00 price target on the stock. Finally, analysts at Deutsche Bank raised their price target on shares of CVS Caremark from $80.00 to $83.00 in a research note on Wednesday, May 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. CVS Caremark presently has a consensus rating of “Buy” and a consensus price target of $76.40.
CVS Caremark Corporation (NYSE:CVS), together with its subsidiaries, is a pharmacy health care provider in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.